CHICAGO (EGMN) - The investigational Janus kinase inhibitor ruxolitinib is superior to best available therapy when it comes to reducing splenomegaly and alleviating symptoms in patients with myelofibrosis, researchers reported at the annual meeting of the American Society of Clinical Oncology.In the randomized, phase III COMFORT-II (Controlled Myelofibrosis Study With Oral Janus-Associated Kinase [JAK] Inhibitor Treatment-II), roughly a third of patients who were given the oral drug had at least...